BACKGROUND: Our objective was to assess the therapeutic noninferiority of dual therapy with darunavir/ritonavir and lamivudine compared to triple therapy with darunavir/ritonavir plus 2 nucleos(t)ides for maintenance of human immunodeficiency virus type 1 (HIV-1) suppression. METHODS: This was a multicenter, open-label, noninferiority trial (margin 12%). Patients with HIV-1 RNA <50 copies/mL for 6 months or longer on triple therapy with darunavir/ritonavir and 2 nucleos(t)ides (tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine) and with no resistance were randomized to continue therapy (n = 128) or switch to darunavir/ritonavir and lamivudine (n = 129). The primary endpoint was the proportion of participants with HIV-RNA <50 copies/mL after 48 weeks of follow-up according to the snapshot algorithm. RESULTS: A total of 249 participants received study drugs (intention-to-treat exposed). The proportion of participants with HIV-RNA <50 copies/mL in the dual- and triple-therapy arms was 88.9% (112/126) and 92.7% (114/123; difference, -3.8%; 95% confidence interval, -11.0 to 3.4), respectively. Four participants in the dual-therapy arm and 2 in the triple-therapy arm developed protocol-defined virological failure. Switching to dual therapy was associated with a significant increase in total, low-density lipoprotein, and high-density lipoprotein (HDL) cholesterol, but not in the total-to-HDL cholesterol ratio. Serious adverse events and study drug discontinuations due to adverse events occurred in 4.8% vs 4.9%P = .97) and in 0.8% (1/126) vs 1.6% P = .55) in dual therapy vs triple therapy, respectively. CONCLUSIONS: Dual therapy with darunavir/ritonavir and lamivudine demonstrated noninferior therapeutic efficacy and similar tolerability compared to triple therapy. CLINICAL TRIALS REGISTRATION: NCT02159599.
BACKGROUND: Our objective was to assess the therapeutic noninferiority of dual therapy with darunavir/ritonavir and lamivudine compared to triple therapy with darunavir/ritonavir plus 2 nucleos(t)ides for maintenance of human immunodeficiency virus type 1 (HIV-1) suppression. METHODS: This was a multicenter, open-label, noninferiority trial (margin 12%). Patients with HIV-1 RNA <50 copies/mL for 6 months or longer on triple therapy with darunavir/ritonavir and 2 nucleos(t)ides (tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine) and with no resistance were randomized to continue therapy (n = 128) or switch to darunavir/ritonavir and lamivudine (n = 129). The primary endpoint was the proportion of participants with HIV-RNA <50 copies/mL after 48 weeks of follow-up according to the snapshot algorithm. RESULTS: A total of 249 participants received study drugs (intention-to-treat exposed). The proportion of participants with HIV-RNA <50 copies/mL in the dual- and triple-therapy arms was 88.9% (112/126) and 92.7% (114/123; difference, -3.8%; 95% confidence interval, -11.0 to 3.4), respectively. Four participants in the dual-therapy arm and 2 in the triple-therapy arm developed protocol-defined virological failure. Switching to dual therapy was associated with a significant increase in total, low-density lipoprotein, and high-density lipoprotein (HDL) cholesterol, but not in the total-to-HDL cholesterol ratio. Serious adverse events and study drug discontinuations due to adverse events occurred in 4.8% vs 4.9%P = .97) and in 0.8% (1/126) vs 1.6% P = .55) in dual therapy vs triple therapy, respectively. CONCLUSIONS: Dual therapy with darunavir/ritonavir and lamivudine demonstrated noninferior therapeutic efficacy and similar tolerability compared to triple therapy. CLINICAL TRIALS REGISTRATION: NCT02159599.
Authors: Mary Clare Masters; Karen M Krueger; Janna L Williams; Lindsay Morrison; Susan E Cohn Journal: Expert Rev Clin Pharmacol Date: 2019-12 Impact factor: 5.045
Authors: Babafemi O Taiwo; Vincent C Marconi; Baiba Berzins; Carlee B Moser; Amesika N Nyaku; Carl J Fichtenbaum; Constance A Benson; Timothy Wilkin; Susan L Koletar; Jonathan Colasanti; Edward P Acosta; Jonathan Z Li; Paul E Sax Journal: Clin Infect Dis Date: 2018-05-17 Impact factor: 9.079
Authors: Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding Journal: JAMA Date: 2018-07-24 Impact factor: 56.272
Authors: Lauren Greenberg; Lene Ryom; Bastian Neesgaard; Gilles Wandeler; Therese Staub; Martin Gisinger; Michael Skoll; Huldrych F Günthard; Alexandra Scherrer; Cristina Mussini; Colette Smith; Margaret Johnson; Stéphane De Wit; Coca Necsoi; Christian Pradier; Ferdinand Wit; Clara Lehmann; Antonella d'Arminio Monforte; Jose M Miró; Antonella Castagna; Vincenzo Spagnuolo; Anders Sönnerborg; Matthew Law; Jolie Hutchinson; Nikoloz Chkhartishvili; Natalia Bolokadze; Jan-Christian Wasmuth; Christoph Stephan; Vani Vannappagari; Felipe Rogatto; Josep M Llibre; Claudine Duvivier; Jennifer Hoy; Mark Bloch; Heiner C Bucher; Alexandra Calmy; Alain Volny Anne; Annegret Pelchen-Matthews; Jens D Lundgren; Lars Peters; Loveleen Bansi-Matharu; Amanda Mocroft Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 20.999
Authors: Douglas Ward; Moti Ramgopal; David J Riedel; Cindy Garris; Shelly Dhir; John Waller; Jenna Roberts; Katie Mycock; Alan Oglesby; Bonnie Collins; Megan Dominguez; James Pike; Joseph Mrus Journal: AIDS Res Treat Date: 2020-07-07
Authors: O T Stirrup; D Asboe; A Pozniak; C A Sabin; R Gilson; N E Mackie; A Tostevin; T Hill; D T Dunn Journal: HIV Med Date: 2020-01-11 Impact factor: 3.180